OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentPhase 2

TST001

TST001 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.